A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

  • STATUS
    Recruiting
  • End date
    Feb 1, 2024
  • participants needed
    280
  • sponsor
    Pfizer
Updated on 7 April 2021
Investigator
Pfizer CT.gov Call Center
Primary Contact
Kurume University Hospital (0.6 mi away) Contact
+220 other location
metastasis
crizotinib

Summary

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment nave and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Details
Condition Non-Small Cell Lung Cancer
Treatment Crizotinib, Lorlatinib
Clinical Study IdentifierNCT03052608
SponsorPfizer
Last Modified on7 April 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note